564 related articles for article (PubMed ID: 29183800)
1. Formulations based on solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for cutaneous use: A review.
Garcês A; Amaral MH; Sousa Lobo JM; Silva AC
Eur J Pharm Sci; 2018 Jan; 112():159-167. PubMed ID: 29183800
[TBL] [Abstract][Full Text] [Related]
2. Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC).
Fang JY; Fang CL; Liu CH; Su YH
Eur J Pharm Biopharm; 2008 Oct; 70(2):633-40. PubMed ID: 18577447
[TBL] [Abstract][Full Text] [Related]
3. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations.
Müller RH; Radtke M; Wissing SA
Adv Drug Deliv Rev; 2002 Nov; 54 Suppl 1():S131-55. PubMed ID: 12460720
[TBL] [Abstract][Full Text] [Related]
4. Solid lipid nanoparticles and nanostructured lipid carriers--innovative generations of solid lipid carriers.
Shidhaye SS; Vaidya R; Sutar S; Patwardhan A; Kadam VJ
Curr Drug Deliv; 2008 Oct; 5(4):324-31. PubMed ID: 18855604
[TBL] [Abstract][Full Text] [Related]
5. SLN and NLC for topical, dermal, and transdermal drug delivery.
Souto EB; Baldim I; Oliveira WP; Rao R; Yadav N; Gama FM; Mahant S
Expert Opin Drug Deliv; 2020 Mar; 17(3):357-377. PubMed ID: 32064958
[No Abstract] [Full Text] [Related]
6. Lipid nanocarriers for dermal delivery of lutein: preparation, characterization, stability and performance.
Mitri K; Shegokar R; Gohla S; Anselmi C; Müller RH
Int J Pharm; 2011 Jul; 414(1-2):267-75. PubMed ID: 21596122
[TBL] [Abstract][Full Text] [Related]
7. Nanostructured lipid carriers (NLCs) versus solid lipid nanoparticles (SLNs) for topical delivery of meloxicam.
Khalil RM; Abd-Elbary A; Kassem MA; Ghorab MM; Basha M
Pharm Dev Technol; 2014 May; 19(3):304-14. PubMed ID: 23528038
[TBL] [Abstract][Full Text] [Related]
8. Impact of lipid dynamic behavior on physical stability, in vitro release and skin permeation of genistein-loaded lipid nanoparticles.
Andrade LM; de Fátima Reis C; Maione-Silva L; Anjos JL; Alonso A; Serpa RC; Marreto RN; Lima EM; Taveira SF
Eur J Pharm Biopharm; 2014 Sep; 88(1):40-7. PubMed ID: 24816130
[TBL] [Abstract][Full Text] [Related]
9. Characterization and biocompatibility evaluation of cutaneous formulations containing lipid nanoparticles.
Eiras F; Amaral MH; Silva R; Martins E; Lobo JMS; Silva AC
Int J Pharm; 2017 Mar; 519(1-2):373-380. PubMed ID: 28131849
[TBL] [Abstract][Full Text] [Related]
10. Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): their benefits as colloidal drug carrier systems.
Uner M
Pharmazie; 2006 May; 61(5):375-86. PubMed ID: 16724531
[TBL] [Abstract][Full Text] [Related]
11. How can lipid nanocarriers improve transdermal delivery of olanzapine?
Iqbal N; Vitorino C; Taylor KM
Pharm Dev Technol; 2017 Jun; 22(4):587-596. PubMed ID: 27876425
[TBL] [Abstract][Full Text] [Related]
12. Lipid nanoparticles loading triptolide for transdermal delivery: mechanisms of penetration enhancement and transport properties.
Gu Y; Yang M; Tang X; Wang T; Yang D; Zhai G; Liu J
J Nanobiotechnology; 2018 Sep; 16(1):68. PubMed ID: 30217198
[TBL] [Abstract][Full Text] [Related]
13. Resveratrol-loaded solid lipid nanoparticles versus nanostructured lipid carriers: evaluation of antioxidant potential for dermal applications.
Gokce EH; Korkmaz E; Dellera E; Sandri G; Bonferoni MC; Ozer O
Int J Nanomedicine; 2012; 7():1841-50. PubMed ID: 22605933
[TBL] [Abstract][Full Text] [Related]
14. Lipid nanocapsules for dermal application: a comparative study of lipid-based versus polymer-based nanocarriers.
Abdel-Mottaleb MM; Neumann D; Lamprecht A
Eur J Pharm Biopharm; 2011 Sep; 79(1):36-42. PubMed ID: 21558002
[TBL] [Abstract][Full Text] [Related]
15. Current State of Lipid Nanoparticles (SLN and NLC) for Skin Applications.
Eroğlu C; Sinani G; Ulker Z
Curr Pharm Des; 2023; 29(21):1632-1644. PubMed ID: 37534479
[TBL] [Abstract][Full Text] [Related]
16. Development of SLN and NLC enriched hydrogels for transdermal delivery of nitrendipine: in vitro and in vivo characteristics.
Bhaskar K; Krishna Mohan C; Lingam M; Jagan Mohan S; Venkateswarlu V; Madhusudan Rao Y; Bhaskar K; Anbu J; Ravichandran V
Drug Dev Ind Pharm; 2009 Jan; 35(1):98-113. PubMed ID: 18665979
[TBL] [Abstract][Full Text] [Related]
17. Natural Lipids as Structural Components of Solid Lipid Nanoparticles and Nanostructured Lipid Carriers for Topical Delivery.
Dobreva M; Stefanov S; Andonova V
Curr Pharm Des; 2020; 26(36):4524-4535. PubMed ID: 32410552
[TBL] [Abstract][Full Text] [Related]
18. Cosmetic features and applications of lipid nanoparticles (SLN, NLC).
Souto EB; Müller RH
Int J Cosmet Sci; 2008 Jun; 30(3):157-65. PubMed ID: 18452432
[TBL] [Abstract][Full Text] [Related]
19. Preclinical safety of solid lipid nanoparticles and nanostructured lipid carriers: Current evidence from in vitro and in vivo evaluation.
Doktorovová S; Kovačević AB; Garcia ML; Souto EB
Eur J Pharm Biopharm; 2016 Nov; 108():235-252. PubMed ID: 27519829
[TBL] [Abstract][Full Text] [Related]
20. Transdermal Lipid Nanocarriers: A Potential Delivery System for Lornoxicam.
Dasgupta S; Ray S; Dey S; Pal P; Mazumder B
Pharm Nanotechnol; 2017; 5(1):32-43. PubMed ID: 28948909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
